# US 2025/0082677 A1 · Long covid medication and method of treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082677 A1
- Document ID: US20250082677A1
- Status: Published application
- Kind: A1
- Application number: 18/244,569
- Filed: 2023-09-11
- Published: 2025-03-13
- Earliest claimed: 2023-09-11
- Inventors: Ellen Kirschner
- Web page: https://patentgrep.com/patent/US20250082677A1

## CPC

- A61K 33/42: Phosphorus; Compounds thereof
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 33/10: Carbonates; Bicarbonates
- A61K 33/26: Iron; Compounds thereof
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/22: for herpes viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods of use for treatment of Long Covid, or other post-viral or other post-infection conditions that result in a toxin induced thickened blood pulp condition (e.g., including but not limited to influenza, zika, herpes, or epstein-barr viruses). The treatment composition includes C29H40N2O4; C9H2N2; and/or C28H38N2O4; and optionally a source of iron. A filler (e.g., CaCO3) or pharmaceutically acceptable carrier may be provided. In the treatment method, treatment composition is administered to a patient, specifically because of the patient's exhibition of symptoms of Long Covid (or other contemplated post-viral or other post-infection condition). The treatment composition can be administered as a single dose. The components thereof have a molecular and/or particle size sufficiently small so as to not induce vomiting, and the single dose administration to the patient is sufficient so that the patient's Long Covid symptoms are relieved within a period of about 10 days.

## Claims

### Claim 1

A composition for use in treatment of Long Covid, or other post-viral or other post-infection conditions that result in a toxin induced thickened blood pulp condition, the composition comprising:
C29H40N2O4;
C9H2N2;
C28H38N2O4; and
a source of iron.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising CaCO3.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the source of iron comprises FePO4.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the composition is administered in a single dose, wherein the single dose includes about 1/300,000 to about 1/750,000 mg of C29H40N2O4, about 1:60,000 to about 1/250,000 mg of C9H2N2, about 1/300,000 to about 1/750,000 mg of C28H38N2O4, about 1 to about 5 mg of the source of iron, and about 1 to about 10 mg of CaCO3.

### Claim 5

A method for treatment of Long Covid, or other post-viral or other post-infection conditions that result in a toxin induced thickened blood pulp condition, the method comprising:
providing a treatment composition comprising:
C29H40N2O4;
C9H2N2; and/or
C28H38N2O4; and
optionally a source of iron; and
administering the treatment composition to a patient, selected because of their exhibiting symptoms of Long Covid, or other post viral infection condition.

### Claim 6 (depends on 5)

The method of claim 5, wherein the treatment composition further comprises CaCO3.

### Claim 7 (depends on 5)

The method of claim 5, wherein the treatment composition includes the source of iron, which comprises FePO4.

### Claim 8 (depends on 5)

The method of claim 5, wherein the treatment composition is administered in a single dose, wherein the single dose includes about 1/300,000 mg to about 1/750,000 mg of C29H40N2O4, about 1/60,000 mg to about 1/250,000 mg of C9H2N2, and about 1/300,000 mg to about 1/750,000 mg of C28H38N2O4.

### Claim 9 (depends on 7)

The method of claim 7, wherein the treatment composition is administered in a single dose, wherein the single dose includes about 1/300,000 mg to about 1/750,000 mg of C29H40N2O4, about 1/60,000 mg to about 1/250,000 mg of C9H2N2, about 1/300,000 mg to about 1/750,000 mg of C28H38N2O4, and about 1 to about 5 mg of FePO4.

### Claim 10 (depends on 5)

The method of claim 5, wherein the method is used to treat Long Covid.

### Claim 11 (depends on 5)

The method of claim 5, wherein the method is used to treat at least one of a post viral infection condition associated with influenza, zika, herpes, or epstein-barr viruses.

### Claim 12

A method for treatment of Long Covid, the method comprising:
providing a treatment composition comprising:
C29H40N2O4;
C9H2N2;
C28H38N2O4; and
optionally a source of iron; and
administering the treatment composition to a patient, selected because of the patient's exhibition of symptoms of Long Covid.

### Claim 13 (depends on 12)

The method of claim 12, wherein the treatment composition further comprises CaCO3.

### Claim 14 (depends on 12)

The method of claim 12, wherein the treatment composition comprises the source of iron, which comprises FePO4.

### Claim 15 (depends on 14)

The method of claim 14, wherein the treatment composition is administered in a single dose, wherein the single dose includes about 1/300,000 mg to about 1/750,000 mg of C29H40N2O4, about 1/60,000 mg to about 1/250,000 mg of C9H2N2, about 1/300,000 mg to about 1/750,000 mg of C28H38N2O4, and about 1 to about 5 mg of FePO4.

### Claim 16 (depends on 12)

The method of claim 12, wherein the treatment composition is administered as a single dose, the components thereof have a molecular or particle size sufficiently small so as to not induce vomiting, and the single dose administration to the patient is sufficient so that the patient's Long Covid symptoms are relieved within a period of about 10 days.

### Claim 17

Use of a treatment composition in a drug or other treatment composition, for treatment of Long Covid, other post-viral, or other post-infection conditions, wherein the composition comprises:
C29H40N2O4;
C9H2N2; and/or
C28H38N2O4.

### Claim 18 (depends on 17)

The use of claim 17, wherein the treatment composition further comprises a source of iron, which comprises FePO4.

### Claim 19

Use of a treatment composition to interfere with the metabolism of COVID-19 or other viruses, wherein the composition comprises:
C29H40N2O4;
C9H2N2; and/or
C28H38N2O4.

### Claim 20 (depends on 19)

The use of claim 19, wherein the treatment composition further comprises a source of iron, which comprises FePO4.
